Introduction: Doxorubicin is one of the most reliable anthracycline chemotherapeutics. Its high efficacy in treating a large range of cancers, however, comes hand in hand with complications. A hallmark of anthracycline drugs, and also their most common side effect, is heart failure caused by the development of dilated cardiomyopathy. Purpose of the study: The purpose of our work is to present the current state of knowledge about the causes of doxorubicin cardiotoxicity and to present known ways to minimize the negative impact on the patient's health. Materials and Methods: We performed a non-systematic review of the Polish and English-language literature available in the database, using the keywords: ,,doxorubicin"; ,,anthracyclines"; ,,cardiotoxicity"; ,,cardiomyopathy"; ,,chemotherapy". Results: Doxorubicin is counted among the first-generation anthracycline cytostatics widely used in cancer chemotherapy. The enormous potential of anthracyclines is a motivator for further attempts to improve these molecules and eliminate side effects. The methods developed so far have led to a reduction in the frequency of cardiovascular incidents, but the risks associated with the use of these drugs are still relatively high and the cost of liposomal forms is high. Summary: The current state of knowledge identifies promising options for improving the well-being of patients undergoing treatment with chemotherapeutic agents. Hopes for effective analogs free of cardiotoxic effects are reasonable, and the use of companion substances is an additional possibility.

Introduction: The number of surgeries requiring sedation continues to increase worldwide. Analgesia is one of the main components of anesthesia used during surgical procedures. Despite improvements in surgical techniques, the invention of new analgesics and a significant expansion of knowledge about the pathophysiology of pain, more than 75% of patients experience postoperative pain. Adequate analgesia reduces postoperative complications and shortens the length of hospitalization. Lidocaine is a local anesthetic also used as an antiarrhythmic drug. Studies report that intravenous administration may find application in perioperative analgesia. Aim of the study: The purpose of our study was to determine in which types of surgery the benefits of IVL (Intravenous lidocaine) are greatest.Methods and Evidence: We reviewed the literature available on PubMed using the words "Intravenous lidocaine"; "Perioperative Lidocaine "; "Postoperative pain".Results: IVL has been shown to have a positive effect on reducing opioid doses, postoperative pain intensity, shortening the duration of postoperative bowel obstruction, faster patient rehabilitation and shortening hospitalization. In non-abdominal surgeries, the greatest benefits have been seen in breast surgery, urology and spinal surgery. Lidocaine has low toxicity; only doses several times higher cause adverse effects.Conclusions: IVL should be used during intraabdominal surgery due to its high efficacy. Further studies on a larger group of patients are needed to better determine the effects of IVL in other surgeries. Keywords: "Intravenous lidocaine"; "Perioperative Lidocaine "; "Postoperative pain".